GMS Ventures & Investments is Director & 10% Owner at Outlook Therapeutics, Inc. (OTLK). They have made 1 open-market trade across 1 company since 2021, most recently 2022-04-21.
CIK 0001804598
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $8.4M since 2021, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| OTLK | 55,816,786 | $27.2M |
Shares reported on the most recent Form 4, priced at the 2022-04-22 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| OTLK | BUY | 2021-02-02 | 2021-02-02 | $1.00 | $8.4M | +94.6% | +39.2% | +81.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.